SEGMENT REPORTING (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of financial information by reportable segments

Financial information by reportable segment is as follows:

	Three Months Ended June 30, 2025
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	94,213	$	117,158	$	—	$	211,371
Less:
Cost of sales (excluding depreciation and amortization)	43,231		31,384		—		74,615
Research and development	11,414		5,121		—		16,535
Selling, general, and administrative	1,389		51,191		29,191		81,771
Depreciation and amortization	—		—		23,281		23,281
Contingent consideration fair value adjustment	—		—		1,277		1,277
Operating (Loss) Income	$	38,179	$	29,462	$	(53,749)	$	13,892
Unrealized gain on investment in equity securities	$	—	$	—	$	332	$	332
Interest expense, net	—		—		(5,438)		(5,438)
Other income, net	—		—		1,739		1,739
Income (Loss) Before Income Tax Expense	$	38,179	$	29,462	$	(57,116)	$	10,525

	Three Months Ended June 30, 2024
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	78,821	$	59,219	$	—	$	138,040
Less:
Cost of sales (excluding depreciation and amortization)	42,014		15,684		—		57,698
Research and development	5,427		1,869		—		7,296
Selling, general, and administrative	1,344		26,349		25,128		52,821
Depreciation and amortization	—		—		14,697		14,697
Contingent consideration fair value adjustment	—		—		359		359
Gain on sale of building	—		—		—		—
Operating (Loss) Income	$	30,036	$	15,317	$	(40,184)	$	5,169
Unrealized loss on investment in equity securities	$	—	$	—	$	(2,712)	$	(2,712)
Interest expense, net	—		—		(4,656)		(4,656)
Other expense, net	—		—		(88)		(88)
Income (Loss) Before Income Tax Expense	$	30,036	$	15,317	$	(47,640)	$	(2,287)

	Six Months Ended June 30, 2025
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	197,253	$	211,240	$	—	$	408,493
Cost of sales (excluding depreciation and amortization)	89,732		57,920		—		147,652
Research and development	18,002		9,097		—		27,099
Selling, general, and administrative	2,797		93,627		61,875		158,299
Depreciation and amortization	—		—		46,172		46,172
Contingent consideration fair value adjustment	—		—		(10,815)		(10,815)
Operating (Loss) Income	$	86,722	$	50,596	$	(97,232)	$	40,086
Unrealized loss on investment in equity securities	$	—	$	—	$	(589)	$	(589)
Interest expense, net	—		—		(10,922)		(10,922)
Other income, net	—		—		1,937		1,937
Income (Loss) Before Income Tax Expense	$	86,722	$	50,596	$	(106,806)	$	30,512

	Six Months Ended June 30, 2024
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	153,635	$	121,835	$	—	$	275,470
Cost of sales (excluding depreciation and amortization)	78,814		28,041		—		106,855
Research and development	13,446		4,361		—		17,807
Selling, general, and administrative	2,354		51,015		47,473		100,842
Depreciation and amortization	—		—		29,383		29,383
Contingent consideration fair value adjustment	—		—		449		449
Gain on sale of building	—		—		(5,347)		(5,347)
Operating (Loss) Income	$	59,021	$	38,418	$	(71,958)	$	25,481
Unrealized gain on investment in equity securities	$	—	$	—	$	6,943	$	6,943
Interest expense, net	—		—		(9,256)		(9,256)
Other expense, net	—		—		(120)		(120)
Income (Loss) Before Income Tax Expense	$	59,021	$	38,418	$	(74,391)	$	23,048